Abacavir: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[ | '''[[Abacavir description|Description]]''' | ||
'''| [[ | '''| [[Abacavir clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Abacavir microbiology|Microbiology]]''' | ||
'''| [[ | '''| [[Abacavir indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Abacavir contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Abacavir warnings and precautions|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Abacavir adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Abacavir overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Abacavir clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[Abacavir dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Abacavir compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | ||
'''| [[ | '''| [[Abacavir directions for use|Directions For Use]]''' | ||
'''| [[ | '''| [[Abacavir how supplied|How Supplied]]''' | ||
'''| [[ | '''| [[Abacavir labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Revision as of 15:50, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Abacavir (ABC) is a nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. It is available under the trade name Ziagen (ViiV Healthcare) and in the combination formulations Trizivir (abacavir, zidovudine and lamivudine) and Kivexa/Epzicom (abacavir and lamivudine). It has been well tolerated: the main side effect is hypersensitivity, which can be severe, and in rare cases, fatal. Genetic testing can indicate whether an individual will be hypersensitive; over 90% of patients can safely take abacavir. However, in a separate study, the risk of heart attack increased by nearly 90%.[1]
Viral strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally sensitive to abacavir (ABC), whereas some strains that are resistant to AZT and 3TC are not as sensitive to abacavir.
Category
Antiretroviral
US Brand Names
ZIAGEN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages
Mechanism of Action
Abacavir is an analog of guanosine (a purine) which is phosphorylated to carbovir triphosphate to interfere with RNA-dependent DNA polymerase resulting in inhibition of viral replication.